08:06 AM EST, 11/27/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Wednesday said updated clinical data from the ongoing Phase 1/2 ABILITY-1 study will be presented as part of an oral podium presentation at the 2024 Immunotherapy Bridge Conference, taking place next week in Naples, Italy.

The oral presentation will include updated clinical data from the monotherapy and combination arms of the Study, which is evaluating MDNA11 in patients with advanced or metastatic solid tumors.